Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
3.
Circulation ; 139(24): 2765-2777, 2019 06 11.
Artículo en Inglés | MEDLINE | ID: mdl-30909726

RESUMEN

BACKGROUND: Metabolic remodeling in heart failure contributes to dysfunctional lipid trafficking and lipotoxicity. Acyl coenzyme A synthetase-1 (ACSL1) facilitates long-chain fatty acid (LCFA) uptake and activation with coenzyme A (CoA), mediating the fate of LCFA. The authors tested whether cardiac ACSL1 overexpression aids LCFA oxidation and reduces lipotoxicity under pathological stress of transverse aortic constriction (TAC). METHODS: Mice with cardiac restricted ACSL1 overexpression (MHC-ACSL1) underwent TAC or sham surgery followed by serial in vivo echocardiography for 14 weeks. At the decompensated stage of hypertrophy, isolated hearts were perfused with 13C LCFA during dynamic-mode 13C nuclear magnetic resonance followed by in vitro nuclear magnetic resonance and mass spectrometry analysis to assess intramyocardial lipid trafficking. In parallel, acyl CoA was measured in tissue obtained from heart failure patients pre- and postleft ventricular device implantation plus matched controls. RESULTS: TAC-induced cardiac hypertrophy and dysfunction was mitigated in MHC-ACSL1 hearts compared with nontransgenic hearts. At 14 weeks, TAC increased heart weight to tibia length by 46% in nontransgenic mice, but only 26% in MHC-ACSL1 mice, whereas ACSL1 mice retained greater ejection fraction (ACSL1 TAC: 65.8±7.5%; nontransgenic TAC: 45.9±7.3) and improvement in diastolic E/E'. Functional improvements were mediated by ACSL1 changes to cardiac LCFA trafficking. ACSL1 accelerated LCFA uptake, preventing C16 acyl CoA loss post-TAC. Long-chain acyl CoA was similarly reduced in human failing myocardium and restored to control levels by mechanical unloading. ACSL1 trafficked LCFA into ceramides without normalizing the reduced triglyceride storage in TAC. ACSL1 prevented de novo synthesis of cardiotoxic C16- and C24-, and C24:1 ceramides and increased potentially cardioprotective C20- and C22-ceramides post-TAC. ACLS1 overexpression activated AMP activated protein kinase at baseline, but during TAC, prevented the reduced LCFA oxidation in hypertrophic hearts and normalized energy state (phosphocreatine:ATP) and consequently, AMP activated protein kinase activation. CONCLUSIONS: This is the first demonstration of reduced acyl CoA in failing hearts of humans and mice, and suggests possible mechanisms for maintaining mitochondrial oxidative energy metabolism by restoring long-chain acyl CoA through ASCL1 activation and mechanical unloading. By mitigating cardiac lipotoxicity, via redirected LCFA trafficking to ceramides, and restoring acyl CoA, ACSL1 delayed progressive cardiac remodeling and failure.


Asunto(s)
Acilcoenzima A/metabolismo , Metabolismo Energético , Insuficiencia Cardíaca/metabolismo , Hipertrofia Ventricular Izquierda/metabolismo , Metabolismo de los Lípidos , Miocardio/metabolismo , Disfunción Ventricular Izquierda/metabolismo , Función Ventricular Izquierda , Remodelación Ventricular , Proteínas Quinasas Activadas por AMP/metabolismo , Anciano , Animales , Transporte Biológico , Ceramidas/metabolismo , Coenzima A Ligasas/genética , Coenzima A Ligasas/metabolismo , Modelos Animales de Enfermedad , Ácidos Grasos/metabolismo , Femenino , Insuficiencia Cardíaca/genética , Insuficiencia Cardíaca/patología , Insuficiencia Cardíaca/fisiopatología , Humanos , Hipertrofia Ventricular Izquierda/genética , Hipertrofia Ventricular Izquierda/patología , Hipertrofia Ventricular Izquierda/fisiopatología , Masculino , Ratones Transgénicos , Persona de Mediana Edad , Miocardio/patología , Oxidación-Reducción , Triglicéridos/metabolismo , Disfunción Ventricular Izquierda/genética , Disfunción Ventricular Izquierda/patología , Disfunción Ventricular Izquierda/fisiopatología
4.
BMC Gastroenterol ; 16: 30, 2016 Feb 29.
Artículo en Inglés | MEDLINE | ID: mdl-26927700

RESUMEN

BACKGROUND: Approximately 2.7 million Americans are chronically infected with hepatitis C virus (HCV). HCV patients with cirrhosis form the largest group of persons at high risk for hepatocellular carcinoma (HCC). Increased oxidative stress is regarded as a major mechanism of HCV-related liver disease progression. Deficiencies in retinoid and carotenoid antioxidants may represent a major modifiable risk factor for disease progression. This study aims to identify key predictors of serum antioxidant levels in patients with HCV, to examine the relationship between retinoid/carotenoid concentrations in serum and hepatic tissue, to quantify the association between systemic measures of oxidative stress and antioxidant status, and to examine the relationship between retinoids and stellate cell activation. METHODS: Patients undergoing liver biopsy (n = 69) provided fasting blood, fresh tissue, urine and completed a diet history questionnaire. Serum and questionnaire data from healthy volunteers (n = 11), normal liver tissue from public repositories and patients without liver disease (n = 11) were also collected. Urinary isoprostanes, serum and tissue retinoid concentrations were obtained by UHPLC-MS-MS. Immunohistochemistry for αSMA was performed on FFPE sections and subsequently quantified via digital image analysis. Associations between urinary isoprostanes, αSMA levels, and retinoids were assessed using Spearman correlation coefficients and non-parametric tests were utilized to test differences among disease severity groups. RESULTS: There was a significant inverse association between serum retinol, lycopene, and RBP4 concentrations with fibrosis stage. Serum ß-carotene and lycopene were strongly associated with their respective tissue concentrations. There was a weak downward trend of tissue retinyl palmitate with increasing fibrosis stage. Tissue retinyl palmitate was inversely and significantly correlated with hepatic αSMA expression, a marker for hepatic stellate cell activation (r = -0.31, P < 0.02). Urinary isoprostanes levels were inversely correlated with serum retinol, ß-carotene, and RBP4. CONCLUSIONS: A decrease in serum retinol, ß-carotene, and RBP4 is associated with early stage HCV. Retinoid and carotenoid levels decline as disease progresses, and our data suggest that this decline occurs early in the disease process, even before fibrosis is apparent. Measures of oxidative stress are associated with fibrosis stage and concurrent antioxidant depletion. Vitamin A loss is accompanied by stellate cell activation in hepatic tissue.


Asunto(s)
Actinas/metabolismo , Carotenoides/metabolismo , Hepatitis C Crónica/metabolismo , Cirrosis Hepática/metabolismo , Hígado/metabolismo , Retinoides/metabolismo , Actinas/sangre , Adulto , Biomarcadores/metabolismo , Biopsia , Carcinoma Hepatocelular , Carotenoides/sangre , Cromatografía Líquida de Alta Presión , Estudios Transversales , Progresión de la Enfermedad , Diterpenos , Ensayo de Inmunoadsorción Enzimática , Femenino , Células Estrelladas Hepáticas/metabolismo , Humanos , Inmunohistoquímica , Isoprostanos/orina , Peroxidación de Lípido , Cirrosis Hepática/patología , Neoplasias Hepáticas , Licopeno , Masculino , Persona de Mediana Edad , Estrés Oxidativo , Retinoides/sangre , Proteínas Plasmáticas de Unión al Retinol/metabolismo , Ésteres de Retinilo , Riesgo , Índice de Severidad de la Enfermedad , Espectrometría de Masas en Tándem , Vitamina A/análogos & derivados , Vitamina A/sangre , Vitamina A/metabolismo , beta Caroteno/sangre , beta Caroteno/metabolismo
5.
J Mol Cell Cardiol ; 94: 1-9, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-26995156

RESUMEN

RATIONALE: Acyl CoA synthetase-1 (ACSL1) is localized at intracellular membranes, notably the mitochondrial membrane. ACSL1 and female sex are suggested to indirectly facilitate lipid availability to the heart and other organs. However, such mechanisms in intact, functioning myocardium remain unexplored, and roles of ACSL1 and sex in the uptake and trafficking of fats are poorly understood. OBJECTIVE: To determine the potential for ACSL1 and sex-dependent differences in metabolic trapping and trafficking effects of long-chain fatty acids (LCFA) within cardiomyocytes of intact hearts. METHODS AND RESULTS: (13)C NMR of intact, beating mouse hearts, supplied (13)C palmitate, revealed 44% faster trans-sarcolemmal uptake of LCFA in male hearts overexpressing ACSL1 (MHC-ACSL1) than in non-transgenic (NTG) males (p<0.05). Acyl CoA content was elevated by ACSL1 overexpression, 404% in males and 164% in female, relative to NTG. Despite similar ACSL1 content, NTG females displayed faster LCFA uptake kinetics compared to NTG males, which was reversed by ovariectomy. NTG female LCFA uptake rates were similar to those in ACSL1 males and ACSL1 females. ACSL1 and female sex hormones both accelerated LCFA uptake without affecting triglyceride content or turnover. ACSL1 hearts contained elevated ceramide, particularly C22 ceramide in both sexes and specifically, C24 in males. ACSL1 also induced lower content of fatty acid transporter-6 (FATP6) indicating cooperative regulation with ACSL1. Surprisingly, ACSL1 overexpression did not increase mitochondrial oxidation of exogenous palmitate, which actually dropped in female ACSL1 hearts. CONCLUSIONS: ACSL1-mediated metabolic trapping of exogenous LCFA accelerates LCFA uptake rates, albeit to a lesser extent in females, which distinctly affects LCFA trafficking to acyl intermediates but not triglyceride storage or mitochondrial oxidation and is affected by female sex hormones.


Asunto(s)
Coenzima A Ligasas/metabolismo , Metabolismo Energético , Ácidos Grasos/metabolismo , Miocardio/metabolismo , Animales , Transporte Biológico , Membrana Celular/metabolismo , Coenzima A Ligasas/genética , Femenino , Expresión Génica , Hormonas Esteroides Gonadales/metabolismo , Pruebas de Función Cardíaca , Hemodinámica , Metabolismo de los Lípidos , Espectroscopía de Resonancia Magnética , Masculino , Ratones , Ratones Transgénicos , Mitocondrias/metabolismo , Oxidación-Reducción , Sarcómeros/metabolismo , Factores Sexuales
6.
Neuropsychopharmacology ; 34(8): 2011-8, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19322170

RESUMEN

Cognitive deficits in schizophrenia are a major source of dysfunction for which more effective treatments are needed. The vasopressin-deficient Brattleboro (BRAT) rat has been shown to have several natural schizophrenia-like deficits, including impairments in prepulse inhibition and memory. We investigated BRAT rats and their parental strain, Long-Evans (LE) rats, in a social discrimination paradigm, which is an ethologically relevant animal test of cognitive deficits of schizophrenia based upon the natural preference of animals to investigate conspecifics. We also investigated the effects of the atypical antipsychotic, clozapine, and the putative antipsychotic, PD149163, a brain-penetrating neurotensin-1 agonist, on social discrimination in these rats. Adult rats were administered saline or one of the three doses of clozapine (0.1, 1.0, or 10 mg/kg) or PD149163 (0.1, 0.3, or 1.0 mg/kg), subcutaneously. Following drug administration, adult rats were exposed to a juvenile rat for a 4-min learning period. Animals were then housed individually for 30 min and then simultaneously exposed to the juvenile presented previously and a new juvenile for 4 min. Saline-treated LE rats, but not BRAT rats, exhibited intact social discrimination as evidenced by greater time spent exploring the new juvenile. The highest dose of clozapine and the two highest doses of PD149163 restored social discrimination in BRAT rats. These results provide further support for the utility of the BRAT rat as a genetic animal model relevant to schizophrenia and drug discovery. The potential of neurotensin agonists as putative treatments for cognitive deficits of schizophrenia was also supported.


Asunto(s)
Clozapina/farmacología , Trastornos del Conocimiento/tratamiento farmacológico , Trastornos Mentales/tratamiento farmacológico , Neurotensina/agonistas , Esquizofrenia/tratamiento farmacológico , Conducta Social , Animales , Antipsicóticos/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/fisiopatología , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/fisiopatología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Conducta Exploratoria/efectos de los fármacos , Conducta Exploratoria/fisiología , Masculino , Trastornos Mentales/etiología , Trastornos Mentales/fisiopatología , Neurotensina/análogos & derivados , Neurotensina/metabolismo , Neurotensina/farmacología , Ratas , Ratas Brattleboro , Ratas Long-Evans , Receptores de Neurotensina/agonistas , Receptores de Neurotensina/metabolismo , Esquizofrenia/complicaciones , Esquizofrenia/fisiopatología , Psicología del Esquizofrénico
7.
Dalton Trans ; (19): 2288-90, 2006 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-16688316

RESUMEN

A new alkyne-containing chelating ligand, 1,2-di(quinolin-8-yl)ethyne, is shown to form a mononuclear 1:1 complex with silver(I) and chelate the metal ion through both nitrogens and the ethyne moiety as seen by UV and NMR spectroscopy as well as X-ray crystallography.


Asunto(s)
Acetileno/análogos & derivados , Quelantes/química , Quinolinas/química , Plata/química , Acetileno/síntesis química , Acetileno/química , Alquinos/síntesis química , Alquinos/química , Quelantes/síntesis química , Cristalografía por Rayos X , Espectroscopía de Resonancia Magnética , Conformación Molecular , Estructura Molecular , Quinolinas/síntesis química , Solventes/química , Espectrofotometría Ultravioleta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...